Artificial intelligence is rapidly reshaping drug discovery, diagnostics, and therapeutic optimization. Natera introduced AI foundational models integrating genomic, clinical, and imaging data to improve biomarker development and immunotherapy response prediction. Twist Bioscience launched a comprehensive genomic profiling panel facilitating targeted oncology research. Additionally, Tempus AI expanded its digital pathology capabilities by acquiring Paige, aiming to build the largest oncology foundation model. These developments underscore AI’s expanding role in precision medicine and molecular diagnostics.